- My News
- All News
- Most Popular
Bigfoot Biomedical announced on Thursday that its Bigfoot Unity diabetes management programme is now available to diabetes clinics and endocrinology practices in select markets across the US. The company said the programme comprises "first-of-its-kind technologies" and a cloud-based platform that connects healthcare providers "seamlessly" to their patients to enable "continuous, proactive care, with or without an office visit."
CEO Jeffrey Brewer remarked that "with these innovative, connected technologies, we can address many of the challenges faced by clinicians," adding that the programme "is designed to act as a real-time partner in diabetes management so clinicians focus on what really matters."
According to Bigfoot, the programme provides physicians, treating patients with type 1 or type 2 diabetes who rely on multiple daily injection insulin therapy, with tools, support services and access to data, enabling them to monitor therapy adherence, analyse data and make therapy adjustments. Additionally, the programme helps clinicians to deliver remote physiologic monitoring for those patients "in a scalable, efficient way," the company added.
Insulin-dosing recommendations on demand
Bigfoot explained that the patient-facing component of the programme is the Bigfoot Unity system, which gained FDA 510(k) clearance last month for patients with type 1 or type 2 diabetes aged 12 and older who have to take multiple injections of insulin every day. The system is integrated with Abbott's FreeStyle Libre 2 continuous glucose monitoring system and features "first-of-its-kind" connected smart pen caps that give insulin-dosing recommendations on demand.
Physician's access to patient data
The programme also features a secure, cloud-based platform, called Bigfoot Clinic Hub, which provides physician's on demand access to data from patients using the Bigfoot Unity system and a FreeStyle Libre 2 sensor. The data are passively captured and uploaded to the Clinic Hub from the system's smart pen caps whenever WiFi or cellular signal is present.
The company noted that availability of the programme, currently in California, Texas, Florida, Pennsylvania, Ohio, New York, New Jersey, Massachusetts, and other New England states, will expand to other markets throughout 2021 and 2022.
To ensure you don't miss other Top Stories like these and news on key healthtech industry developments, sign up for our free daily e-newsletter here.
Did you like this article?